Innovent Biologics Inc., a biopharmaceutical company that develops, manufactures and commercializes medicines, has entered a ...

Innovent Biologics (IVBIY) collaborates with Roche (RHHBY) to develop the antibody-drug conjugate IBI3009 for small cell lung ...

Global markets have recently shown mixed performances, with the S&P 500 and Nasdaq Composite both closing out a strong year despite some volatility and profit-taking towards year-end. In this ...

Roche is wasting no time in getting out its checkbook in 2025, signing a new biobucks-heavy pact that aims to add another new ...

Innovent inks exclusive global license agreement with Roche to advance the development of IBI3009, a novel DLL3 targeted ADC candidate: San Francisco, US Friday, January 3, 2025, ...

Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high quality ...

Roche acquires ADC rights from Innovent for lung cancer treatment in $1 billion deal Roche strengthens its global foothold in ...

IBI3009 is an ADC designed to target DLL3, a molecule overexpressed in certain cancers, mainly small-cell lung cancer. The collaboration aims to advance it for the benefit of patients with ...

China’s Innovent Biologics today announced a collaboration and exclusive license agreement with Swiss pharma giant Roche to ...

Roche has once again returned to China to bolster its antibody-drug conjugate pipeline, this time striking a licensing deal ...

Innovent and Roche have entered a partnership and exclusive licence agreement to accelerate the development of IBI3009.